Regulus Therapeutics Inc.
RGLS
$3.54
$0.051.43%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 3,166.99% | -87.75% | |||
| Gross Profit | -3,166.99% | 87.75% | |||
| SG&A Expenses | 5.46% | -2.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.63% | 24.06% | |||
| Operating Income | 9.63% | -24.06% | |||
| Income Before Tax | 9.04% | -27.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.04% | -27.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.04% | -27.42% | |||
| EBIT | 9.63% | -24.06% | |||
| EBITDA | 9.66% | -24.23% | |||
| EPS Basic | 9.08% | -25.47% | |||
| Normalized Basic EPS | 9.02% | -25.42% | |||
| EPS Diluted | 9.08% | -25.47% | |||
| Normalized Diluted EPS | 9.02% | -25.42% | |||
| Average Basic Shares Outstanding | 0.04% | 1.56% | |||
| Average Diluted Shares Outstanding | 0.04% | 1.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||